Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,567,360
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
30,103,833
-
Shares change
-
-538,713
-
Total reported value, excl. options
-
$200,460,000
-
Value change
-
-$13,223,479
-
Put/Call ratio
-
0%
-
Number of buys
-
44
-
Number of sells
-
-37
-
Price
-
$6.66
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q4 2021
92 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30,103,833 shares
of 98,567,360 outstanding shares and own 30.54% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8,740,887 shares), FMR LLC (3,753,737 shares), Nextech Invest AG (1,910,029 shares), WASATCH ADVISORS INC (1,773,690 shares), RA CAPITAL MANAGEMENT, L.P. (1,742,186 shares), BlackRock Inc. (1,579,287 shares), MORGAN STANLEY (1,390,889 shares), VANGUARD GROUP INC (1,311,666 shares), EcoR1 Capital, LLC (1,060,010 shares), and Nantahala Capital Management, LLC (1,006,462 shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.